Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with key products including various injections and capsules that are unique in the market and covered by national medical insurance [2]. Financial Performance - For Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.90 million yuan, representing a significant year-on-year decline of 960.04%. The gross profit margin stood at 66.62% [3]. Market Position - As of July 1, ST Jingfeng's stock closed at 6.06 yuan, reflecting an increase of 1.68%. The rolling price-to-earnings (PE) ratio reached 37.67, with a total market capitalization of 5.33 billion yuan. In comparison, the average PE ratio for the chemical pharmaceutical industry is 54.81, and the industry median is 32.58, placing ST Jingfeng at the 96th position within the industry [1][3]. Capital Flow - On July 1, ST Jingfeng experienced a net inflow of 9.70 million yuan in principal funds, although the overall trend over the past five days showed a net outflow of 2.44 million yuan [1].
ST景峰收盘上涨1.68%，滚动市盈率37.67倍，总市值53.31亿元
Sou Hu Cai Jing·2025-07-01 08:35